A Randomized, Double-blind, Placebo-controlled, Forced Dose-escalation, Multi-center Pilot Study to Evaluate the Lipid Regulating Effects of TRIA-662 (1-methylnicotinamide Chloride)
Phase of Trial: Phase II
Latest Information Update: 12 Feb 2016
At a glance
- Drugs N-1-methylnicotinamide (Primary)
- Indications Hyperlipidaemia
- Focus Therapeutic Use
- Sponsors Cortria Corporation
- 07 Jun 2017 Biomarkers information updated
- 26 Jan 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 03 Aug 2015 Planned End Date changed from 1 Sep 2015 to 1 Oct 2015 as per ClinicalTrials.gov record.